Aurobindo Pharma Limited, a prominent player in the pharmaceutical industry, has recently disclosed significant changes in its senior management team. The company has announced the departure of two key executives, marking a shift in its leadership structure.

Senior Management Changes

Details of Departures

Dr. Mandepudi Sudhakara Reddy's Resignation

Dr. Mandepudi Sudhakara Reddy, who held the position of Associate President of Corporate QA, has decided to step down from his role. According to the company's disclosure:

• Dr. Reddy submitted his resignation letter on August 9, 2025.
• He cited acceptance of a new opportunity aligning with his career aspirations as the reason for his departure.
• The company has accepted his resignation, and he will be relieved from his duties effective from the close of business hours on November 4, 2025.

Mr. K.P. Ravinatha Shetty's Retirement

Mr. K.P. Ravinatha Shetty, who served as the President of Operations, has retired from the company. The details of his retirement are as follows:

• Mr. Shetty retired upon reaching superannuation on November 3, 2025.
• He will be officially relieved from his services effective November 4, 2025.

Regulatory Compliance

Aurobindo Pharma Limited has made this disclosure in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided the necessary details as required by the regulatory framework, ensuring transparency in its corporate governance practices.

These changes in the senior management team may have implications for Aurobindo Pharma's operations and strategic direction.

Aurobindo Pharma Limited, a major player in the pharmaceutical industry, has announced a strategic move to strengthen its presence in Latin America. The company's wholly owned stepdown subsidiary, Eugia Pharma B.V, has incorporated a new wholly owned subsidiary in Chile named Eugia Pharma Chile SpA.

Key Details of the New Subsidiary

Strategic Implications

This move signifies Aurobindo Pharma's commitment to expanding its global footprint, particularly in the Latin American market. By establishing a direct presence in Chile, the company aims to strengthen its position in the region's pharmaceutical sector.

Regulatory Compliance

The company has confirmed that no governmental or regulatory approvals were required for this incorporation. This information was disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Corporate Structure

Eugia Pharma Chile SpA is incorporated as a wholly owned subsidiary of Eugia Pharma B.V, which itself is a wholly owned stepdown subsidiary of Aurobindo Pharma Limited. This structure makes the new Chilean entity a related party of Aurobindo Pharma Limited.

Market Implications

As the new subsidiary was only recently incorporated, it's too early to assess its financial impact. However, this expansion into Chile suggests Aurobindo Pharma's interest in the Chilean market's potential. This move could potentially lead to increased market share and revenue opportunities for the company in South America.

Aurobindo Pharma's strategic expansion into Chile demonstrates the company's approach to capturing new markets and diversifying its geographical presence in the evolving global pharmaceutical landscape.